Overview

A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types

Status:
Active, not recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
A study evaluating the drug levels of ipilimumab alone and in combination with nivolumab applied under the skin in various tumor types
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Ipilimumab
Nivolumab